Opfolda (Miglustat)

Miglustat inhibits the enzyme glucosylceramide synthase, which is essential for the first step in glycosphingolipid production. By blocking this enzyme, the drug lowers the amount of substrate that accumulates in cells affected by certain lysosomal storage diseases.

The specific dose of Opfolda is determined by the prescribing physician based on the patient’s age, weight, disease severity, and renal function. Dosage regimens are individualized and should follow the prescriber’s instructions.

Miglustat is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and under close medical supervision.

To request Opfolda, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The main alternative to miglustat is enzyme replacement therapy (ERT), which supplies the missing enzyme directly. Miglustat offers a substrate reduction approach that can be taken orally, whereas ERT requires intravenous infusions. Choice of therapy depends on disease stage, patient preference and clinical considerations.

Opfolda should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

Opfolda is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and hepatic dysfunction. Patients should be educated to seek immediate medical attention if they experience intense abdominal pain, rash, swelling, or signs of liver injury.

Opfolda is contraindicated in patients with severe hepatic impairment, known hypersensitivity to miglustat, or those taking strong CYP3A4 inducers that markedly reduce drug exposure. Caution is also advised in individuals with renal insufficiency or uncontrolled diabetes.